T-Cell Acute Lymphoblastic Leukaemia

Dear Colleagues, 

T-cell acute lymphoblastic leukemias (T-ALL) are a rare form of hematological cancers that often have specific mutations and translocations, as well as having aggressive behavior, requiring urgent chemotherapy and, in many cases, an allogeneic stem cell transplant (SCT). T-ALL are 15–25% of all ALL diagnosed, but have a worse prognosis than B-ALL in both pediatric and adult settings. Understanding the several genetic changes of the leukemic cells has helped to find target therapies, such as small molecules and kinase inhibitors, to specifically act on the cancer cells and have less overall toxicity than conventional cytotoxic chemotherapy, which remains the current standard of care for up-front treatment. Moreover, the evaluation of minimal residual disease (MRD), either detecting specific T-cell receptor rearrangements by multiparametric flow cytometry or by the polymerase chain reaction, has a pivotal role in guiding therapeutic decision making. MRD-positive patients have a worse prognosis and benefit from more aggressive treatment, including HSCT. This Special Issue offers an open access forum that aims to bring together a collection of original research and review articles addressing the expanding field of T-cell acute leukemias. We hope to provide a stimulating resource of topics related to T-cell acute leukemias, such as molecular pathogenesis, epidemiology, treatments, and minimal residual disease. This summary and the keywords are intended as a guide for potential authors, as well as to clarify the background and aims of the Special Issue (for recent examples of Special Issue websites, please see https://www.mdpi.com/journal/cells/special_issues/cellular_stress).

Dr. Benedetto Bruno
Dr. Giuseppe Lanzarone
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• T-cell leukemias
• molecular pathogenesis
• immune phenotype
• T-cell leukemia epidemiology
• T-cell ontogeny
• transplantation in T-cell leukemia
• target therapies